LYON, France & NEW YORK–(BUSINESS WIRE)–The MEDICREA® Group (Euronext Growth Paris: FR0004178572 –
ALMED ; OTCQX Best Market –MRNTF), pioneering the transformation of
spinal surgery through Artificial Intelligence, predictive modeling and
patient specific implants with its UNiD® ASI (Adaptive Spine
Intelligence) proprietary software platform, services and technologies,
announced today that the United States Patent Office has recently issued
the Company additional key patents related to the UNiD ASI proprietary
technology platform.
Over the last few years, MEDICREA® has had a leading role in
revolutionizing the personalized spine surgery. Its disruptive ideas and
innovative patient specific technologies have been instrumental in
shaping the future spine industry business model associating precise
analysis of each patient and pre-op planning expert services to the
implants. The Company has been actively protecting these innovations
through an aggressive patent strategy building a IP portfolio that
includes 10 independent families, 5 issued patents and 16 pending
applications.
The 3 newly allowed patents (U.S. Patent No 10,318,655; 10,314,657;
10,292,770) are directed to fundamental technologies and methods
embedded in the UNiD ASI platform, a breakthrough in spine surgery.
These additional allowances enable the Company to further expand its
existing patent portfolio as the Company continues to protect its
technology directed to:
-
The use of Artificial Intelligence and Predictive Modeling in spine
surgery -
Systems and methods for generating data to produce patient-specific 2D
and 3D rods - Patient-specific screw planning and screw kit generation
- Patient-specific cage planning and production
- Intra operative monitoring device
MEDICREA®’s proprietary UNiD ASI™ technology is a comprehensive suite of
services designed to help surgeons improve their patient’s outcomes. By
leveraging artificial intelligence and the latest clinical research, the
platform enables the surgeon to plan cases preoperatively. The
Artificial Intelligence embedded within the platform allows a surgeon to
visualize the compensatory mechanisms above and below the instrumented
spine that will most likely occur based on the surgeon’s surgical plan.
The surgeons work hand-in-hand with the UNiD Lab™ biomedical engineers
who create several surgical plans and identify the one that would give
the surgeon’s patient the best outcome.
Through rigorous and centralized processes, MEDICREA® improves the
content of its clinical database with each case, allowing the
proprietary technology to continuously refine the algorithms behind its
predictive model. With over 4000 cases performed through the UNiD ASI™
technology platform, all including patient-specific implants, this
technology undoubtedly met a market need. The Company plans to pursue
its efforts to spread the technology and grow its clinical database.
Denys Sournac, Chief Executive Officer of MEDICREA®, concludes,
“MEDICREA® is the pioneer in this new approach of spinal treatment and
was able to file the very first patents covering these innovations. For
this reason, the new patents issued create strong barriers to entry for
competitors. It enables the company to maintain its competitive
advantage and strengthen its leading position in the market place that
is now obviously evolving into this direction. The Company will pursue
its permanent efforts of enhancing its very unique predictive model with
the aim to always improve patient clinical outcomes”.
About MEDICREA® (www.medicrea.com)
Through the lens of predictive medicine, MEDICREA® leverages its
proprietary software analysis tools with big data and machine learning
technologies supported by an expansive collection of clinical and
scientific data. The Company is well-placed to streamline the efficiency
of spinal care, reduce procedural complications and limit time spent in
the operating room.
Operating in a $10 billion marketplace, MEDICREA® is a Small and Medium
sized Enterprise (SME) with 200 employees worldwide, which includes 50
who are based in the U.S. The Company has an ultra-modern manufacturing
facility in Lyon, France housing the development and production of 3D-
printed titanium patient-specific implants.
For further information, please visit: medicrea.com.
Connect with MEDICREA®
FACEBOOK | INSTAGRAM | TWITTER | WEBSITE | YOUTUBE
MEDICREA® is listed on
EURONEXT Growth Paris
ISIN: FR 0004178572
Ticker: ALMED
LEI: 969500BR1CPTYMTJBA37
MEDICREA® is traded on
OTCQX Best Market
Tickers: MRNTY & MRNTF
Contacts
MEDICREA®
Denys SOURNAC
Founder, Chairman and CEO
[email protected]
Fabrice KILFIGER
Chief Financial Officer
[email protected]
Tel:
+33 (0)4 72 01 87 87
